At the time of writing, Arvinas Inc [ARVN] stock is trading at $47.67, up 3.65%. An important factor to consider is whether the stock is rising or falling in short-term value. The ARVN shares have gain 3.68% over the last week, with a monthly amount drifted -2.73%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, March 2024, Arvinas to Participate in Upcoming Investor Conferences. In a post published today on Yahoo Finance, Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in three upcoming investor conferences:.
From an analyst’s perspective:
Arvinas Inc [NASDAQ: ARVN] stock has seen the most recent analyst activity on February 28, 2024, when Oppenheimer reiterated its Outperform rating and also revised its price target to $80 from $95. Previously, Citigroup downgraded its rating to Neutral on February 14, 2024, and elevated its price target to $55. On February 01, 2024, Goldman initiated with a Buy rating and assigned a price target of $70 on the stock. Wells Fargo upgraded its rating to a Overweight and increased its price target to $63 on December 19, 2023. Jefferies upgraded its rating to a Buy but $40 remained the price target by the analyst firm on December 06, 2023. Guggenheim upgraded its rating to Buy for this stock on November 20, 2023. In a note dated October 23, 2023, Wedbush upgraded an Outperform rating on this stock and revised its target price from $27 to $24.
For the past year, the stock price of Arvinas Inc fluctuated between $13.57 and $53.08. Currently, Wall Street analysts expect the stock to reach $75 within the next 12 months. Arvinas Inc [NASDAQ: ARVN] shares were valued at $47.67 at the most recent close of the market. An investor can expect a potential return of 57.33% based on the average ARVN price forecast.
Analyzing the ARVN fundamentals
According to Arvinas Inc [NASDAQ:ARVN], the company’s sales were 78.50M for trailing twelve months, which represents an -213.42% plunge. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -5.11%, Pretax Profit Margin comes in at -4.64%, and Net Profit Margin reading is -4.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -0.7 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.89 points at the first support level, and at 44.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 49.35, and for the 2nd resistance point, it is at 51.04.
Arvinas Inc [ARVN] reported earnings per share of -$2.53 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.27/share, meaning a difference of -$1.26 and a surprise factor of -99.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.18 per share as compared to estimates of -$1.58 per share, a difference of $0.4 representing a surprise of 25.30%.
Ratios To Look Out For
It is important to note that Arvinas Inc [NASDAQ:ARVN] has a current ratio of 4.98. On the other hand, the Quick Ratio is 4.98, and the Cash Ratio is 1.23. Considering the valuation of this stock, the price to sales ratio is 41.34, the price to book ratio is 4.91.
Transactions by insiders
Recent insider trading involved Houston John G, President and CEO, that happened on Feb 23 ’24 when 5196.0 shares were sold. Chief Financial Officer, Cassidy Sean A completed a deal on Feb 23 ’24 to sell 1702.0 shares. Meanwhile, Chief Scientific Officer Taylor Ian sold 1701.0 shares on Feb 23 ’24.
